The new safety mandate driving AI-ready pharmacovigilance
Deepanshu Saini, Director of Program Management at IQVIA reflects on the interplay between safety and AI pharmacovigilance.
Comment & Opinion
When trillion‑member libraries meet physics: what diversity really means
UK–US zero‑tariff deal pricing reforms position UK as global hub for new medicines
JPM26: Immunocore Signals Entry into type 1 diabetes
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Transformative arrival of oral weight loss medicines in the US
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency
